0M
0ME.F Twist Bioscience Corp
- Market cap
- EUR 8.48B
- P/E
- -
- P/B
- 19.37x
- ROE
- -32.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is 0ME.F undervalued?
Graham numberThe Graham number of Twist Bioscience Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Twist Bioscience Corp fundamental analysis
No fundamental analysis for Twist Bioscience Corp yet.
Twist Bioscience Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Twist Bioscience Corp
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DN…
Full company profileTwist Bioscience Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Twist Bioscience Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 10.8M | 25.4M | 54.4M | 90.1M | 132M | 204M | 245M | 313M | 377M | 444M |
| Gross Profit | - | -13.3M | -6.76M | 6.96M | 28.7M | 51.7M | 84.2M | 89.7M | 133M | 191M | 231M |
| Operating Income | - | -58.5M | -70.6M | -109M | -118M | -153M | -249M | -207M | -176M | -136M | -144M |
| EBITDA | - | -53.1M | -64.0M | -100.0M | -132M | -154M | -228M | -178M | -144M | -111M | -118M |
| Net Income | - | -59.3M | -71.2M | -108M | -140M | -152M | -218M | -205M | -209M | -77.7M | -146M |
| EPS | - | -2.23 | -2.54 | -3.28 | -3.10 | -3.07 | -3.87 | -3.56 | -3.55 | -1.28 | -2.33 |
| Balance Sheet | |||||||||||
| Total Assets | - | 85.7M | 116M | 187M | 399M | 702M | 961M | 776M | 614M | 642M | 672M |
| Total Liabilities | - | 219M | 317M | 34.9M | 62.6M | 121M | 172M | 153M | 142M | 169M | 227M |
| Shareholders' Equity | - | -133M | -201M | 152M | 336M | 581M | 789M | 623M | 473M | 473M | 446M |
| Cash & Short-term Investments | - | 31.2M | 80.8M | 46.7M | 93.7M | 466M | 379M | 286M | 226M | 183M | 117M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -38.6M | -51.3M | -66.2M | -87.9M | -142M | -112M | -124M | -142M | -64.1M | -47.6M | -55.0M |
| Capital Expenditure | 0.00 | 6.59M | 3.69M | 14.8M | 9.87M | 27.1M | 102M | 27.8M | 5.08M | 28.0M | 37.0M |
| Free Cash Flow | - | -57.9M | -69.9M | -103M | -152M | -139M | -226M | -170M | -69.2M | -75.6M | -92.0M |
| Ratios | |||||||||||
| ROE | - | - | - | -70.8% | -41.6% | -26.2% | -27.6% | -32.8% | -44.2% | -16.4% | -32.8% |
| ROA | - | -69.2% | -61.5% | -57.6% | -35.1% | -21.7% | -22.7% | -26.4% | -34.0% | -12.1% | -21.7% |
| Net Profit Margin | - | -550.8% | -280.2% | -198.0% | -155.3% | -114.9% | -107.0% | -83.5% | -66.7% | -20.6% | -32.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Twist Bioscience Corp dividends
Twist Bioscience Corp has not paid dividends in the last 9 fiscal years.
Who owns Twist Bioscience Corp
- Insiders 0.90%
- Institutions 99.10%
- Public & others 0.00%
- Shares outstanding 66.3M
- Free float 61.9M
Twist Bioscience Corp company profile
- Company name
- Twist Bioscience Corp
- Ticker
- 0ME.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 979
- Fiscal year end
- September
- Address
- 681 Gateway Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 800 719 0671
- Website
- twistbioscience.com
About Twist Bioscience Corp
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Twist Bioscience Corp management
10- Dr. Emily Marine Leproust Ph.D.Co-Founder, Board Chair & CEO · born 1973
- Dr. Patrick John Finn Ph.D.President & COO · born 1972
- Mr. Adam LaponisChief Financial Officer · born 1977
- Mr. Dennis Cho J.D.Chief Legal Officer & Corporate Secretary · born 1971
- Ms. Paula GreenSenior Vice President of Human Resources · born 1968
- Mr. Robert F. WernerVP & Chief Accounting Officer · born 1973
- Mr. Siyuan ChenChief Technology Officer
- Dr. Michael Fero Ph.D.Chief Information Officer
- Dr. Colby Souders Ph.D.Chief Scientific Officer
- Ms. Nicole MorenoSenior Vice President of Sales & Support